Status: Not yet recruiting
A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of NXC-201 Compared With Daratumumab With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) in Newly Diagnosed Systemic AL Amyloidosis
The purpose of this study is to evaluate the efficacy and safety of NXC-201 compared with Dara-CyBorD (daratumumab-cyclophosphamide-bortezomib-dexamethasone) in the treatment of newly diagnosed amyloid light chain (AL) amyloidosis participants.
Participants needed: 260
Trial details
Phase: Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: Nexcella Inc.Updated: Jul 16, 2026
Eligibility criteria
Eastern Cooperative Oncology Group performance status score ≤2 [+3]
Prior therapy for AL amyloidosis or multiple myeloma [+4]